Online inquiry

IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14742MR)

This product GTTS-WQ14742MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in B cell acute lymphoblastic leukemia (B cell ALL), Refractory B-lineage non-Hodgkin lymphoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ14742MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ188MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ10689MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ7229MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ10627MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ9737MR IVTScrip™ mRNA-Anti-TFRC, JR-141(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JR-141
GTTS-WQ11296MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ4730MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BOS161721
GTTS-WQ2562MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW